June 7 was the day of the college entrance exam, and the minimally invasive stent-valve team of cardiothoracic surgery led by Prof. Meng Xu of Anzhen Hospital in Beijing also went through a big exam, successfully completing two cases of transapical minimally invasive stent-valve implantation of aortic valves, which is the first time this procedure has been carried out domestically after the official launch of the homegrown J-Valve stent-valve. This is the first time that this operation was carried out in China after the domestic J-Valve stent valve was officially launched. The two 80-year-old patients who underwent the surgery, one with poor heart function and the other with chronic obstructive pulmonary disease (COPD), had extremely poor lung function and could not tolerate conventional extracorporeal cardiac surgery.
Zhang Haibo, chief physician of cardiovascular surgery at Beijing Anzhen Hospital, said that traditional heart surgery generally requires opening the chest cavity, so that the heart stops, through the extracorporeal circulation to maintain the functioning of the body, the patient, so that the surgery leaves a relatively large trauma. Minimally invasive technology only needs to open a small hole in the body 2-3 centimeters, while not open the chest, the heart does not stop beating, do not have to rely on the extracorporeal circulation, will be within the diameter of 21-27 millimeters of the valve implanted directly into the heart.
The implanted J-Valve stent valve, a valve with a unique programmed release of the positioning key function designed independently by China and possessing its own intellectual property rights, is one of the few medical innovations in China in recent years, and is a milestone in the development of China's minimally invasive valve technology. This product is not only the first minimally invasive interventional valve marketed via the apical route in China, but also the only one in the world so far that is suitable for both aortic stenosis and insufficient closure in aortic valve replacement.
Zhang Haibo said that in the past 10 years, the source of high-tech devices for heart valves mainly relied on imports from abroad, which were not only very expensive, but also went through a lot of formalities. Now the valve produced by China itself, the corresponding core indicators have been comparable to the previous imported products. It is worth mentioning that this is the only product in the valve category that has been exported to foreign countries in the reverse direction of technology. Currently, Canada has already begun production, and Europe will also begin, which represents that this "Chinese heart" has gained the recognition of the international community, and further enhances China's influence in the field of minimally invasive valves in the world.
In the game with the international medical equipment enterprises, the domestic medical equipment has been in the running status. When the domestic medical devices have completed the accumulation from scratch, even if it is from the start, but as long as you insist on independent innovation, you can gradually realize the leap from "0 to 1", into the lead formation, to achieve the "comeback".